论文部分内容阅读
目的:评价重组甘精胰岛素联合拜糖苹对老年2型糖尿病患者的疗效和安全性。方法:50例老年T2DM患者分为重组甘精胰岛素联合拜糖苹(A组)和混胰岛素(B组)进行治疗,观察治疗前后FBG、2hBG、HbA1c、BMI、血糖波动幅度(MAGE)、低血糖的频率及程度等情况。结果:治疗后两组FBG、2hBG、HbA1c下降(P<0.05),A组低血糖发生率差异无统计学意义及MAGE均低于B组(P<0.05),A组体重下降0.5kg,B组体重增加1.2kg,差异无统计学意义(P>0.05)。结论:重组甘精胰岛素联合拜糖苹可降低老年T2DM患者血糖,且低血糖发生率低,安全性高。
Objective: To evaluate the efficacy and safety of recombinant glargine and besipar in elderly type 2 diabetic patients. Methods: A total of 50 elderly patients with T2DM were divided into two groups: group A and group B, and FBG, 2hBG, HbA1c, BMI, MAGE, The frequency and extent of blood sugar and so on. Results: After treatment, the FBG, 2hBG and HbA1c in two groups decreased (P <0.05), the incidence of hypoglycemia in group A was lower than that in group B (P <0.05) Group weight increased 1.2kg, the difference was not statistically significant (P> 0.05). Conclusion: Recombinant insulin glargine combined with besacibosy can reduce the blood sugar in elderly patients with T2DM, and the incidence of hypoglycemia is low and safe.